Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate

In vivo study was performed to determine the tolerability and pharmacokinetics of ISIS 104838, a phosphorothioate antisense oligonucleotide targetting human tumour necrosis factor alpha (TNF‐α) mRNA, following multi‐dose administration via intravenous and oral routes. Oral tablet formulations of ISI...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2004-06, Vol.93 (6), p.1431-1439
Main Authors: Raoof, Araz A., Chiu, Peter, Ramtoola, Zeibun, Cumming, Iain K., Teng, Chingleou, Weinbach, Susan P., Hardee, Greg E., Levin, Arthur A., Geary, R.S.
Format: Article
Language:English
Subjects:
absorption enhancer
Administration, Oral
Animals
antisense
bioavailability
Biological and medical sciences
Biological Availability
Chemistry, Pharmaceutical
Decanoic Acids - administration & dosage
Decanoic Acids - blood
Decanoic Acids - pharmacokinetics
Dogs
Female
General pharmacology
Male
Medical sciences
multi-dose tolerability
Oligonucleotides, Antisense - administration & dosage
Oligonucleotides, Antisense - blood
Oligonucleotides, Antisense - pharmacokinetics
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
sodium caprate
Tablets, Enteric-Coated
Tissue Distribution - drug effects
Tissue Distribution - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In vivo study was performed to determine the tolerability and pharmacokinetics of ISIS 104838, a phosphorothioate antisense oligonucleotide targetting human tumour necrosis factor alpha (TNF‐α) mRNA, following multi‐dose administration via intravenous and oral routes. Oral tablet formulations of ISIS 104838 were pre‐formulated with the permeation enhancer, sodium caprate, in an enteric‐coated solid dosage form. The average plasma bioavailability of ISIS 104838 was 1.4% relative to IV. The tissue distribution profile was similar following both routes of administration, with highest concentrations observed in the kidney followed by the liver, lymph nodes and spleen. Plasma bioavailability underestimated the tissue accumulation of ISIS 104838 observed 1 day after the last dose. Mean systemic tissue bioavailability ranged from 2.0 to 4.3%, relative to IV tissues, and was dependent on tissue type. No marked differences were noted in the pharmacokinetic parameters following multi‐dosing either via intravenous or oral routes. All formulations administered were well tolerated. This paper reports the first evaluation of solid oral dosage forms comprising sodium caprate and an antisense oligonucleotide. Furthermore, this study demonstrates the oral delivery of ISIS 104838 from solid oral dose formulations, with the achievement of comparable tissue concentrations of the oligonucleotide to that of the intravenous treatment. © 2004 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 93: 1431–1439, 2004
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.20051